Cerebrolysin vs Semax: A Research Reference
Two compounds, two separate research records. This reference sets Cerebrolysin and Semax against each other on parameters a laboratory can independently verify.
Compound profiles
Cerebrolysin in the indexed record
The literature on Cerebrolysin is a substantial body of work: 667 PubMed-indexed records, alongside 42 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Cochrane Database Syst Rev, Prog Brain Res, spanning 2016–2023.
- Cerebrolysin for acute ischaemic stroke — Cochrane Database Syst Rev, 2023. PMID: 37818733
- Cerebrolysin for acute ischaemic stroke — Cochrane Database Syst Rev, 2020. PMID: 32662068
- Cerebrolysin for acute ischaemic stroke — Cochrane Database Syst Rev, 2017. PMID: 28430363
- Cerebrolysin for acute ischaemic stroke — Cochrane Database Syst Rev, 2016. PMID: 27918088
Semax in the indexed record
Semax returns 207 indexed records on PubMed, a moderate record with no registered studies currently listed on ClinicalTrials.gov.
Recent indexed work appears in ACS Chem Neurosci, Bioinorg Chem Appl, Br J Pharmacol, spanning 2020–2026.
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice — Br J Pharmacol, 2025. PMID: 40692165
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Functional Connectomic Approach to Studying Selank and Semax Effects — Dokl Biol Sci, 2020. PMID: 32342318
- Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats — Neuropeptides, 2021. PMID: 33418449
How the literature differs
The indexed record is not symmetrical between these two compounds. Cerebrolysin carries 460 more indexed records than Semax, which means published methodology, characterisation data and replication attempts are more readily located for Cerebrolysin. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (42 vs 0) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Side-by-side research profile
| Parameter | Cerebrolysin | Semax |
|---|---|---|
| PubMed indexed records | 667 | 207 |
| Registered studies (ClinicalTrials.gov) | 42 | 0 |
| Literature depth | Extensive | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
Cerebrolysin and Semax sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Cerebrolysin describes conditions validated for Cerebrolysin: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Semax without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Selecting between them for a study design
Cerebrolysin and Semax are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Cerebrolysin) generally offers more methodological precedent.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Storage and stability
Lyophilised peptide is the stable form. Held sealed at -20°C and shielded from light, it tolerates long storage; once reconstituted that tolerance drops sharply and the working solution is treated as short-lived.
Each freeze-thaw cycle costs integrity, which is why reconstituted material is normally split into single-use aliquots.
Frequently asked questions
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Which of Cerebrolysin or Semax has more published research?
Cerebrolysin, with 667 indexed PubMed records against 207.
Are Cerebrolysin and Semax the same compound?
No. They are structurally distinct research compounds with separate literature records — 667 indexed records for Cerebrolysin and 207 for Semax.
Related references
- Semax — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.